BridgeBio Pharma
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. BridgeBio Pharma's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 88% to $9,303,000. Profit margin reached -6914%. Total operating expenses were $614,227,000.
Profit Margin
| 2017 | 0 | -30.56M | |
|---|---|---|---|
| 2018 | 0 | -130.74M | |
| 2019 | 40.56M | -260.43M | -642.1% |
| 2020 | 8.24M | -483.92M | -5866.47% |
| 2021 | 69.71M | -639.29M | -917% |
| 2022 | 77.64M | -493.96M | -636.16% |
| 2023 | 9.30M | -643.20M | -6913.92% |
BBIO Income Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 9.30M | 77.64M | 69.71M | 8.24M | 40.56M | 0 | 0 |
Cost of revenue | 2.44M | 3.43M | 3.11M | 3.08M | 2.5M | 0 | 260K |
Gross profit | 6.85M | 74.21M | 66.60M | 5.16M | 38.06M | 0 | -260K |
Operating exp. | |||||||
Research and development | 455.71M | 402.89M | 454.13M | 337.04M | 209.94M | 140.07M | 30.55M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 614.22M | 546.08M | 646.34M | 482.73M | 304.3M | 183.66M | 43.85M |
Operating income | -607.37M | -471.87M | -579.74M | -474.48M | -266.24M | -183.66M | -43.85M |
Other income (expenses), net | -45.88M | -12.78M | -6.70M | -31.00M | -22.34M | 14.75M | 26K |
Income before tax | -653.25M | -484.65M | -586.45M | -505.48M | -288.58M | -169.45M | -43.83M |
Income tax expense | 0 | 9.31M | 52.84M | -21.56M | -28.14M | 16.75M | -13.48M |
Net income | -643.20M | -493.96M | -639.29M | -483.92M | -260.43M | -130.74M | -30.56M |
Earnings per share | |||||||
Basic EPS | -3.95 | -3.35 | -4.43 | -4.1 | -2.48 | -1.42 | -0.33 |
Diluted EPS | -3.95 | -3.35 | -4.43 | -4.1 | -2.48 | -1.42 | -0.33 |
| Data source | Data source | Data source | Data source | Data source |